By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Bristol-Myers Squibb Company 

345 Park Avenue

New York  New York  10154  U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020


SEARCH JOBS

Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.

YEAR FOUNDED:

1858

LEADERSHIP:

Founder: Edward Robinson Squibb

CEO: Giovanni Caforio, MD

CFO: Charles Bancroft

CLINICAL TRIAL:

Please click here for clinical trial information.

JOB OPPORTUNITY:

Please click here for Bristol-Myers Squibb job opportunities.

PRODUCTS:

Please click here to see all products.

For more information, visit
www.bms.com and follow us on www.twitter.com/BMSNEWS.

FOLLOW BRISTOL-MYERS SQUIBB:





Key Statistics


Email:
Ownership: Public

Web Site: Bristol-Myers Squibb
Employees:
Symbol: BMY
 





Collaborations

Gilead 

PanVera LLC 

Pharmagene Laboratories Limited 

Johnson & Johnson 

Amersham Biosciences 

Lexicon Genetics Incorporated 

Athersys  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Merck & Co.  Diabetes

Affinimark Technologies Inc. 

GlaxoSmithKline (North Carolina) 

Medarex, Inc. 

Gilead (Durham, NC) 

Phyton Biotech  - Cancer

Gilead (Seattle, WA) 





Company News
Bristol-Myers Squibb (BMY) Release: Encouraging Survival Observed With Opdivo (Nivolumab) Plus Yervoy(Ipilimumab) With Longer Follow-Up In First-Line Advanced Non-Small Cell Lung Cancer, In Updated Phase 1b Checkmate -012 Study 12/5/2016 12:52:33 PM
CytomX Announces Fourth Target Selection By Bristol-Myers Squibb (BMY) Under Strategic Oncology Collaboration 12/5/2016 8:26:05 AM
European Commission (EC) Approves Bristol-Myers Squibb (BMY)'s Opdivo(Nivolumab) For The Treatment Of Adult Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant And Treatment With Brentuximab Vedotin 11/23/2016 10:51:16 AM
QuintilesIMS Forms New Collaboration With Bristol-Myers Squibb (BMY), Eli Lilly (LLY), Merck KGaA (MKGAF.PK), Darmstadt, Germany, And Pfizer (PFE) To Generate Real World Insights On Usage Of Anti-Cancer Therapies Across Europe 11/22/2016 7:55:18 AM
Bristol-Myers Squibb (BMY) And Enterome Announce Immuno-Oncology Collaboration Focused On Microbiome-Derived Biomarkers, Drug Targets And Bioactive Molecules 11/16/2016 8:10:20 AM
Bristol-Myers Squibb (BMY) Release: Interim Phase 1/2 Data Show Encouraging Clinical Benefit For Lirilumab In Combination With Opdivo (Nivolumab) In Patients With Advanced Platinum Refractory Squamous Cell Carcinoma Of The Head And Neck 11/14/2016 12:52:52 PM
Bristol-Myers Squibb (BMY) Release: Opdivo (Nivolumab) And Yervoy (Ipilimumab) Regimen Shows Promising Efficacy And Safety In Previously Treated Patients With Advanced Form Of Bladder Cancer 11/14/2016 12:50:37 PM
Bristol-Myers Squibb (BMY) Showcases Rheumatoid Arthritis And Immunoscience Commitment With Depth Of Research At 2016 American College of Rheumatology And Association Of Rheumatology Health Professionals Annual Meeting 11/14/2016 11:46:46 AM
With Bristol-Myers Squibb (BMY), Genentech (RHHBY) and Merck & Co. (MRK) Expanding in the Bay Area, Some Wonder if the Real Estate Boom is Too Much 11/14/2016 6:02:49 AM
TARGET PharmaSolutions Partners With Bristol-Myers Squibb (BMY), Offering A New Platform To Collect Real World Data 11/11/2016 10:28:21 AM
12345678910...
//-->